EMAIL THIS PAGE TO A FRIEND

Neurobiology of disease

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.


PMID 25731749

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant Parkinson's disease (PD). LRRK2 contains functional GTPase and kinase domains. The most common G2019S mutation enhances the kinase activity of LRRK2 in vitro whereas G2019S LRRK2 expression in cultured neurons induces toxicity in a kinase-dependent manner. These observations suggest a potential role for kinase activity in LRRK2-associated PD. We have recently developed a novel rodent model of PD with progressive neurodegeneration induced by the adenoviral-mediated expression of G2019S LRRK2. In the present study, we further characterize this LRRK2 model and determine the contribution of kinase activity to LRRK2-mediated neurodegeneration. Recombinant human adenoviral vectors were employed to deliver human wild-type, G2019S or kinase-inactive G2019S/D1994N LRRK2 to the rat striatum. LRRK2-dependent pathology was assessed in the striatum, a region where LRRK2 protein is normally enriched in the mammalian brain. Human LRRK2 variants are robustly expressed throughout the rat striatum. Expression of G2019S LRRK2 selectively induces the accumulation of neuronal ubiquitin-positive inclusions accompanied by neurite degeneration and the altered distribution of axonal phosphorylated neurofilaments. Importantly, the introduction of a kinase-inactive mutation (G2019S/D1994N) completely ameliorates the pathological effects of G2019S LRRK2 in the striatum supporting a kinase activity-dependent mechanism for this PD-associated mutation. Collectively, our study further elucidates the pathological effects of the G2019S mutation in the mammalian brain and supports the development of kinase inhibitors as a potential therapeutic approach for treating LRRK2-associated PD. This adenoviral rodent model provides an important tool for elucidating the molecular basis of LRRK2-mediated neurodegeneration.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2701263
Anti-DCTN4 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2107220
Anti-DCTN4 antibody produced in rabbit, affinity isolated antibody
SAB2105017
Anti-DCTN4, (N-terminal) antibody produced in rabbit, affinity isolated antibody
GW22005A Anti-GTF2H1 (ab1) antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
GW22005B Anti-GTF2H1 (ab2) antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
AV100811
Anti-GTF2H1 antibody produced in rabbit, IgG fraction of antiserum
SAB2104463
Anti-GTF2H1 antibody produced in rabbit, affinity isolated antibody
SAB3700370 Anti-Guinea Pig IgG (H+L) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3700391 Anti-Guinea Pig IgG (H+L), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3700406 Anti-Guinea Pig IgG (H+L), F(ab) fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3700335 Anti-Guinea Pig IgG F(ab′)2 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
L0169
Anti-LRRK2 (C-terminal) antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution
HPA014293
Anti-LRRK2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
GW22431A Anti-NUP62 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
HPA005435
Anti-NUP62 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2101664
Anti-NUP62 antibody produced in rabbit, affinity isolated antibody
SAB1410438
Anti-NUP62 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2501155
Anti-TH (C-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
WH0002965M1
Monoclonal Anti-GTF2H1 antibody produced in mouse, clone 1F12-1B5, purified immunoglobulin, buffered aqueous solution
SAB1403894
Monoclonal Anti-GTF2H1, (C-terminal) antibody produced in mouse, clone 4B9, purified immunoglobulin, buffered aqueous solution
WH0081631M1
Monoclonal Anti-MAP1LC3B antibody produced in mouse, clone 4E11, purified immunoglobulin, buffered aqueous solution
SAB1405293
Monoclonal Anti-MAP1LC3B antibody produced in mouse, clone 4G7, purified immunoglobulin, buffered aqueous solution
WH0023636M2
Monoclonal Anti-NUP62 antibody produced in mouse, clone 2D3, purified immunoglobulin, buffered aqueous solution
SAB1404985
Monoclonal Anti-NUP62 antibody produced in mouse, clone 1F12, purified immunoglobulin, buffered aqueous solution
SAB1305528 MONOCLONAL ANTI-PARK8 (LRRK2) antibody produced in mouse, clone 133AT720, IgG fraction of antiserum, buffered aqueous solution
SAB1305527 MONOCLONAL ANTI-PARK8 (LRRK2) antibody produced in mouse, clone 133AT1218, IgG fraction of antiserum, buffered aqueous solution